AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $218.77, giving the company a market capitalization of 387.52B. It carries a P/E multiple of 165.44 and pays a dividend yield of 3.0%.
As of 2026-01-24, AbbVie(ABBV) stock has fluctuated between $215.88 and $219.82. The current price stands at $218.77, placing the stock +1.3% above today's low and -0.5% off the high.
The AbbVie(ABBV)'s current trading volume is 5.82M, compared to an average daily volume of 7.26M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
In mid-January 2026, AbbVie reported positive Phase 3 results for its bispecific antibody epcoritamab in relapsed/refractory diffuse large B-cell lymphoma, and...
West Pharmaceutical Services (NYSE:WST) has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On Body Delivery System to AbbVie. The d...
Advertisement Phase 3 lymphoma data puts AbbVie (ABBV) oncology in focus AbbVie (ABBV) is drawing fresh attention after reporting Phase 3 results for epcorita...
Analyst ratings
63%
of 32 ratingsMore ABBV News
AbbVie (NYSE:ABBV) reported positive Phase 3 EPCORE DLBCL-1 results for epcoritamab as a monotherapy in relapsed or refractory diffuse large B-cell lymphoma. T...
Berenberg raised the firm’s price target on AbbVie (ABBV) to $275 from $270 and keeps a Buy rating on the shares. The firm upped its forecasts for AbbVie’s Skyr...
Key Points Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie's immunosuppressant portfolio helps it to...
These stocks sport dividend yields ranging from 2.9% to 5.5%. The power of investing in dividend-paying stocks is often underappreciated. Many people assume di...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.